<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480151</url>
  </required_header>
  <id_info>
    <org_study_id>GP-AP2020-01</org_study_id>
    <nct_id>NCT04480151</nct_id>
  </id_info>
  <brief_title>ECLS Versus IMPELLA™ as Bridge to LVAD (ECI-BLAD)</brief_title>
  <acronym>ECI-BLAD</acronym>
  <official_title>ExtraCorporeal Life Support (ECLS) Versus IMPELLA™ Pump as Bridge to Left Ventricular Assist Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this retrospective observational multicenter study the authors tested the hypothesis that
      the use of IMPELLA™ pump as bridge to bridge, by giving the opportunity of active
      rehabilitation, should improve patient's outcomes after the implantation of Left Ventricular
      Assist Device (LVAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      End stage heart failure patients admitted in Intensive Care Unit (ICU) for refractory
      cardiogenic shock requiring short-term mechanical circulatory support as a bridge to a
      long-term LVAD might benefit from early mobilization and rehabilitation with IMPELLA™
      inserted via the axillary artery. The aim of this study is to compare the early
      rehabilitation and outcomes after LVAD implantation between patients previously treated by
      IMPELLA™ or ExtraCorporeal Life Support (ECLS)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients alive in the surgery ward, not requiring intravenous access and walking (John Hopkins highest level of mobility (JH-HLM) scale = 8 at 30 days after the LVAD implantation</measure>
    <time_frame>Day 30 after Left Ventricular Assist Device (LVAD) implantation</time_frame>
    <description>Proportion of patients alive in the surgery ward, not requiring intravenous access and walking (John Hopkins highest level of mobility (JH-HLM) scale = 8) at 30 days after the LVAD implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication and rehabilitation under Short-term Mechanical Circulatory support</measure>
    <time_frame>The day of Left Ventricular Assist Device (LVAD) implantation</time_frame>
    <description>Duration of support, bleeding, hemolysis, surgical re-exploration, thombus, renal replacement therapy, blood products transfusion, stroke, tracheal extubation, mobilization (chair, walking and ergometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ dysfunction before LVAD implantation</measure>
    <time_frame>The day before LVAD implantation</time_frame>
    <description>Need for mechanical ventilation, Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication Under LVAD</measure>
    <time_frame>The day of Intensive Care Unit (ICU) discharge</time_frame>
    <description>bleeding, right ventricular dysfunction, vasoplegia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>The day of Short Term Mechanical Circulatory Support (STMCS) implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>The day of LVAD implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 1 post LVAD implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 3 post LVAD implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 5 post LVAD implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 7 post LVAD implantation</time_frame>
    <description>Organ dysfunction assessed by Sequential Organ Failure Assessment (SOFA) score [0= best outcome to 24 = worst outcome]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>1 month after LVAD implantation</time_frame>
    <description>mortality after LVAD implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>3 months after LVAD implantation</time_frame>
    <description>mortality after LVAD implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital status</measure>
    <time_frame>6 months after LVAD implantation</time_frame>
    <description>mortality after LVAD implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>up to Intensive Care Unit (ICU) discharge (not more than 6 months after LVAD implantation)</time_frame>
    <description>Intensive Care Unit length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>up to hospital discharge (not more than 6 months after LVAD implantation)</time_frame>
    <description>hospital length of stay</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>End-stage Heart Failure</condition>
  <arm_group>
    <arm_group_label>IMPELLA™ alone as bridge to LVAD</arm_group_label>
    <description>patients assisted by IMPELLA™ pump alone during the days preceding the implantation of long term LVAD (at least 48 hours for patients for whom an ECLS was previously used)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECLS alone or with IMPELLA™ as bridge to LVAD</arm_group_label>
    <description>patients assisted by ECLS (ExtraCorporeal life support) alone or simultaneously with IMPELLA™ until the implantation of LVAD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>retrospective study: standard of care</description>
    <arm_group_label>ECLS alone or with IMPELLA™ as bridge to LVAD</arm_group_label>
    <arm_group_label>IMPELLA™ alone as bridge to LVAD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients implanted by IMPELLA™ pump or ECLS as a bridge to long duration LVAD
        between January 2012 and December 2018 in five university hospital centers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients supported with IMPELLA™ or ECLS for refractory cardiogenic shock as a bridge
             to long duration LVAD

        Exclusion Criteria:

          -  Patient refusing to give access to their medical chart

          -  Guardianship and curactorship

          -  Deprived of liberty

          -  short term mechanical circulatory system weaned before LVAD implantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre OUATTARA, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre OUATTARA, MD, PhD</last_name>
    <phone>557656866</phone>
    <phone_ext>+33</phone_ext>
    <email>alexandre.ouattara@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>BORDEAUX UNIVERSITY HOSPITAL Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexandre OUATTARA, MD, PhD</last_name>
      <phone>557656866</phone>
      <phone_ext>+33</phone_ext>
      <email>alexandre.ouattara@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Astrid QUESSARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiogenic shock</keyword>
  <keyword>end stage heart failure</keyword>
  <keyword>bridge to bridge</keyword>
  <keyword>bridge to decision</keyword>
  <keyword>left ventricular assist device</keyword>
  <keyword>IMPELLA™</keyword>
  <keyword>ECLS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

